Edition:
India

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

7.88USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
52,553
52-wk High
$7.98
52-wk Low
$4.60

Summary

Name Age Since Current Position

Weidong Yin

48 2003 Chairman of the Board, President, Chief Executive Officer, Secretary

Nan Wang

46 2013 Chief Financial Officer

Ming Xia

38 2011 Vice President - Sales and Marketing of Sinovac Beijing

Simon Anderson

53 2004 Independent Director

Jue Lee

47 2012 Independent Director

Yuk Lam Lo

68 2006 Independent Director

Meng Mei

58 2012 Independent Director

Stephanie Carrington

IR Contact Officer

Biographies

Name Description

Weidong Yin

Mr. Weidong Yin is Chairman of the Board, President, Chief Executive Officer, Secretary of Sinovac Biotech Ltd., since September 2003. Mr. Yin is also the general manager of Sinovac Biotech and the chairman of Sinovac Hong Kong, Tangshan Yian and Sinovac Dalian. He is the former general manager of Tangshan Yian Bioengineering Co., Ltd., and previously he worked as a medical doctor in infectious disease at the China Center for Disease Control and Prevention, Tangshan City, Hebei province. Dr. Yin has been dedicated to hepatitis research for over 20 years and was instrumental in the development of Healive. In addition, Dr. Yin has been appointed as the principal investigator by the Chinese Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He is also the president of Zhongguancun Listed Companies Association. He obtained his MBA from the National University of Singapore.

Nan Wang

Ms. Nan Wang has been appointed as the Chief Financial Officer of Sinovac Biotech Ltd., effective June 1, 2013. has served as the Vice General Manager of Sinovac Beijing since 2001 where she oversees business development and clinical research. From 1988 to 1993, Ms. Wang was a researcher in biology at the Life Science College of Peking University, PRC. From 1993 to 2001, she worked as a manager at SinoBioway. Ms. Wang received her bachelor’s degree in biology from Peking University and her master degree from University of International Business and Economics, PRC. Ms. Wang also received a diploma in financial management from Beijing College for Entrepreneurs, PRC in 2003.

Ming Xia

Mr. Ming Xia is Vice President - Sales and Marketing of Sinovac Beijing of Sinovac Biotech Ltd. since 2011. Mr. Ming Xia has over 15 years’ experience in vaccine sales and marketing in China. He joined Sinovac in 2002 and has served as Regional Sales Manager, National Sales Manager and Sales Director at Sinovac. Mr. Xia obtained his bachelor degrees in Biochemistry at Anhui University and in International Trade at Shanghai Institute of Foreign Trade. Mr. Xia has made significant contributions to our sales revenue growth in previous years with outstanding leadership and performance results. He kept his top record of generating sales revenue for many years after joining Sinovac. He is a leader with creativity and developed the sales strategy for our existing products. Mr. Ming Xia organized the reform on sales and marketing strategy to meet the change of the market situation.

Simon Anderson

Mr. Simon J. Anderson is Independent Director of Sinovac Biotech Ltd., since July 2004. Mr. Anderson is a member of our audit, compensation, and corporate governance and nominating committees. Mr. Anderson provides consulting expertise in the areas of regulatory compliance, exchange listings and financial operations. He was admitted as a member of the Institute of Chartered Accountants in British Columbia in 1986. Mr. Anderson serves as chief financial officer of companies listed on North American stock exchanges, including IBC Advanced Alloys Corp., which manufactures and processes alloys at its U.S. plants. Mr. Anderson also serves as a director of Simba Gold Corp., a gold exploration company.

Jue Lee

Mr. Jue Lee is Independent Director of Sinovac Biotech Ltd. since May 2011. He is a Principal at SAIF Partners, growth venture capital funds focused on China. SAIF Partners IV L.P. is a shareholder in Sinovac Biotech Ltd. Mr. Lee has more than 15 years of experience across private equity investment, corporate finance, and business development in China. Before becoming a member of the SAIF team in 2007, he had served as the Chief Financial Officer of Topsec Holdings from 2006 to 2007. From 2004 to 2005, he worked as a Principal at RimAsia Capital Partners. Prior to RimAsia Capital Partners, Mr. Lee served in various positions at Delta Associates, the exclusive advisor to Asia Equity Infrastructure Fund, CNK Telecommunications Limited, H&Q Asia Pacific, and Salomon Brothers Inc. in New York. Currently, he is a non-executive director on the boards of Yayi International Inc. (OTC: YYIN) and China Hanking Holdings Limited (SEHK: 03788). Mr. Lee graduated from Amherst College in Massachusetts, USA in 1990 and obtained a Bachelor of Arts degree in Philosophy.

Yuk Lam Lo

Mr. Yuk Lam Lo is Independent Director of Sinovac Biotech Ltd., since March 2006. Mr. Lo is a member of the audit, compensation and corporate governance and nominating committees. Mr. Lo was heavily involved in several committees of the HKSAR Government. He had been appointed a Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. Currently Mr. Lo is serving as a Member of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, a Director of the Chinese Manufacturers’ Association of Hong Kong (CMA) and Chairman of the Innovation and Technology Committee of CMA. Mr. Lo is also the Hononary Founding Chairman of Hong Kong Bio-Organization. In the educational area, Mr. Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is a member of the Advisory Committee of the Vocational Training Council, an Executive Vice-President of Asian College of Management, Adjunct Professor of the Chinese University of Hong Kong and Honorary Professor of several universities in China. In China, Mr. Lo was a Consultant to the Economic Bureau of Changchun and a Member of the Advisory Committee of the Shenzhen Municipal Science and Technology Bureau. At present, he is a Consultant of the Centre for Disease Control and Prevention of China. In the business sector, Mr. Lo is the Chairman of Lo’s Associates Ltd., vice-Chairman of Santai Eco-Fishery Ltd., vice-Chairman of APlus OTC Health Group Ltd., Senior Advisor of Questmark Capital Management Sdn. Bhd., and Senior Director of Questmark Asia Ltd. Mr. Lo is an Independent Director of South East Group Ltd. (0726.HK) and Shangpharma (NYSE:SHP).

Meng Mei

Mr. Meng Mei is Independent Director of Sinovac Biotech Ltd., since March 2012. Mr. Mei is the chairman of compensation committee, and member of the audit and corporate governance and nominating committees. Mr. Mei founded TusPark, a science park established by Tsinghua University in 1994, to incubate high growth companies. He has been the director of TusPark’s development Center since its inception. Mr. Mei is also the Chairman of TusPark Co., Ltd., which is engaged in the development, construction, and management of TusPark and is providing services to enterprises based in TusPark. TusPark is also involved in venture capital investments in China. Mr. Mei sits on the judging expert panel of China’s National Science & Technology Award. He has developed courses on entrepreneurship and new venture formation as a Tsinghua University professor and an entrepreneur. Mr. Mei holds a bachelor’s degree in automation from Tsinghua University, PRC.

Stephanie Carrington

Basic Compensation

Name Fiscal Year Total

Weidong Yin

105,632

Nan Wang

--

Ming Xia

--

Simon Anderson

--

Jue Lee

--

Yuk Lam Lo

--

Meng Mei

--

Stephanie Carrington

--
As Of  31 Dec 2005

Options Compensation